tbuckley/cabot-search huggingface dataset:
Screening for Colorectal Cancer
Authors: Alfred I. Neugut
Journal: Annals of Internal Medicine (1990)

Letters1 December 1990Screening for Colorectal CancerAlfred I. Neugut, MD, PhDAlfred I. Neugut, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-11-899_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:In a recent analysis of colorectal cancer screening, Eddy (1) mentions the concept of using colonoscopy for screening asymptomatic persons at average risk, a notion that we have previously suggested (2) and that will likely be explored with great interest in the future. The logic for such an approach is based on several premises, the main one being the importance of adenomatous polyps as a positive finding in a colorectal cancer screening examination. In the few studies of colonoscopy done in asymptomatic, persons at average risk, investigators have found adenomatous polyp rates virtually identical to those in...References1. Eddy D. Screening for colorectal cancer. Ann Intern Med. 1990;113:373-84. LinkGoogle Scholar2. NeugutForde AK. Screening colonoscopy: has the time come? Am J Gastroenterol. 1988;83:295-7. MedlineGoogle Scholar3. JohnsonGurneyVolpe DMR. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk [Abstract]. Gastroenterology. 1988:94:209. Google Scholar4. LiebermanDenbergSmith DTF. Screening for colon malignancy with colonoscopy in asymptomatic subjects [Abstract]. Gastrointest Endosc. 1989;35:174. Google Scholar5. MaiFoutchSanowski HTR. Hypercholesterolemia as a risk factor for colorectal adenomas in asymptomatic men [Abstract]. Gastrointest Endosc. 1989;35:174. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Alfred I. Neugut, MD, PhD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1990Volume 113, Issue 11Page: 899-900KeywordsCancer screeningColonoscopyColorectal cancerColorectal cancer screeningForecasting ePublished: 1 December 2008 Issue Published: 1 December 1990 PDF downloadLoading ...
Neutral tumor evolution in myeloma is associated with poor prognosis
Authors: David C. Johnson, Oleg Lenive, Jonathan Mitchell, Graham Jackson, Roger Owen, Mark Drayson, Gordon Cook, John R. Jones, Charlotte Pawlyn, Faith E. Davies, Brian A. Walker, Christopher Wardell, Walter M. Gregory, David Cairns, Gareth J. Morgan, Richard S. Houlston, Martin F. Kaiser
Journal: Blood (2017)
Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy
Authors: Daniel T. Pederick, Kay L. Richards, Sandra G. Piltz, Raman Kumar, Stefka Mincheva-Tasheva, Simone A. Mandelstam, Russell C. Dale, Ingrid E. Scheffer, Jozef Gecz, Steven Petrou, James N. Hughes, Paul Q. Thomas
Journal: Neuron (2018)
Comment on Ekblad et al. Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample. Diabetes Care 2017;40:751–758
Authors: Erfan Ayubi, Saeid Safiri
Journal: Diabetes Care (2017)

We have read with great interest the article by Ekblad et al. (1). The authors showed that in multivariable analysis insulin resistance (IR) and higher levels of insulin can be independent predictors of poorer verbal fluency performance and of a greater decline in verbal fluency during 11 years after adjusting for age, sex, and education (1). We would like to congratulate the authors on their published results in the high-quality journal Diabetes Care, which offer great insight into the association between diabetes and Alzheimer disease and cognitive impairment. However, it should be noted that some …
単一蛍光プローブは生細胞の原形質膜における明確に識別と同時に画像化液体秩序と脂質非秩序ミクロドメインを可能にする【Powered by NICT】
Authors: Tian Minggang, Liu Yong, Sun Yuming, Zhang Ruoyao, Feng Ruiqing, Zhang Ge, Guo Lifang, Li Xuechen, Yu Xiaoqiang, Sun Jing Zhi, He Xiuquan
Journal: Biomaterials (2017)
<i>D</i><sub>LCO</sub>: adjust for lung volume, standardised reporting and interpretation
Authors: Brian L. Graham, Vito Brusasco, Felip Burgos, Brendan G. Cooper, Robert Jensen, Adrian Kendrick, Neil R. MacIntyre, Bruce R. Thompson, Jack Wanger
Journal: European Respiratory Journal (2017)

D.C. Johnson proposed that an adjustment of the predicted value for the diffusing capacity of the lung for carbon monoxide ( D LCO) based on the measured and predicted lung volume be included in the report of D LCO test results. An interpretation algorithm is also proposed. A correction of the predicted value for D LCO based on the measured lung volume is not recommended <http://ow.ly/KFn730cPJ9n>
Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter
Authors: Valéry L. Payen, Myriam Y. Hsu, Kristin S. Rädecke, Elisabeth Wyart, Thibaut Vazeille, Caroline Bouzin, Paolo E. Porporato, Pierre Sonveaux
Journal: Cancer Research (2017)

Extracellular acidosis resulting from intense metabolic activities in tumors promotes cancer cell migration, invasion, and metastasis. Although host cells die at low extracellular pH, cancer cells resist, as they are well equipped with transporters and enzymes to regulate intracellular pH homeostasis. A low extracellular pH further activates proteolytic enzymes that remodel the extracellular matrix to facilitate cell migration and invasion. Monocarboxylate transporter MCT1 is a passive transporter of lactic acid that has attracted interest as a target for small-molecule drugs to prevent metastasis. In this study, we present evidence of a function for MCT1 in metastasis beyond its role as a transporter of lactic acid. MCT1 activates transcription factor NF-κB to promote cancer cell migration independently of MCT1 transporter activity. Although pharmacologic MCT1 inhibition did not modulate MCT1-dependent cancer cell migration, silencing or genetic deletion of MCT1 in vivo inhibited migration, invasion, and spontaneous metastasis. Our findings raise the possibility that pharmacologic inhibitors of MCT1-mediated lactic acid transport may not effectively prevent metastatic dissemination of cancer cells. Cancer Res; 77(20); 5591-601. ©2017 AACR.
Characterization of Odorant Receptors from a Non-ditrysian Moth, Eriocrania semipurpurella Sheds Light on the Origin of Sex Pheromone Receptors in Lepidoptera
Authors: Jothi Kumar Yuvaraj, Jacob A. Corcoran, Martin N. Andersson, Richard D. Newcomb, Olle Anderbrant, Christer Löfstedt
Journal: Molecular Biology and Evolution (2017)

Pheromone receptors (PRs) are essential in moths to detect sex pheromones for mate finding. However, it remains unknown from which ancestral proteins these specialized receptors arose. The oldest lineages of moths, so-called non-ditrysian moths, use short-chain pheromone components, secondary alcohols, or ketones, so called Type 0 pheromones that are similar to many common plant volatiles. It is, therefore, possible that receptors for these ancestral pheromones evolved from receptors detecting plant volatiles. Hence, we identified the odorant receptors (ORs) from a non-ditrysian moth, Eriocrania semipurpurella (Eriocraniidae, Lepidoptera), and performed functional characterization of ORs using HEK293 cells. We report the first receptors that respond to Type 0 pheromone compounds; EsemOR3 displayed highest sensitivity toward (2S, 6Z)-6-nonen-2-ol, whereas EsemOR5 was most sensitive to the behavioral antagonist (Z)-6-nonen-2-one. These receptors also respond to plant volatiles of similar chemical structures, but with lower sensitivity. Phylogenetically, EsemOR3 and EsemOR5 group with a plant volatile-responding receptor from the tortricid moth Epiphyas postvittana (EposOR3), which together reside outside the previously defined lepidopteran PR clade that contains the PRs from more derived lepidopteran families. In addition, one receptor (EsemOR1) that falls at the base of the lepidopteran PR clade, responded specifically to β-caryophyllene and not to any other additional plant or pheromone compounds. Our results suggest that PRs for Type 0 pheromones have evolved from ORs that detect structurally-related plant volatiles. They are unrelated to PRs detecting pheromones in more derived Lepidoptera, which, in turn, also independently may have evolved a novel function from ORs detecting plant volatiles.
Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1.
Authors: Elisa A. Rozeman, Aafke Meerveld-Eggink, Johannes V. Van Thienen, John B. A. G. Haanen, Christian U. Blank
Journal: Journal of Clinical Oncology (2016)

e21011 Background: Combination of T-cell checkpoint blockade by anti-CTLA4 (ipilimumab, IPI) and anti-PD-1 (nivolumab, NIV) is one the most promising therapies in patients with late stage melanoma. It induces superior response rates (57.6%) as compared to single NIV (43.7%) or IPI (19.0%) therapy (Checkmate 067 study). This superior efficacy is, however, associated with a high percentage of ≥ grade 3 adverse events (AEs)(55.0% versus 16.3 and 27.3%). The combination therapy is currently not available in the Netherlands, which prompted physicians to treat patients with short-term IPI followed directly by NIV or pembrolizumab (PEM). Methods: In this retrospective analysis, patients were included who were treated with short-term IPI q3wk (two courses day 0 and 21), directly followed by anti-PD-1 (starting at day 22 and onwards depending on the schedule (every 2 wks for NIV and 3 wks for PEM)). Patients were analyzed for toxicity (% ≥ 3 grade AEs), best overall objective response rate (BORR) and disease control rate (DCR) as measured by RECIST 1.1. Results: Between May and December 2015, 41 patients with advanced melanoma were treated with IPI directly followed by anti-PD-1 (30/41 PEM, 11/41 NIV). Baseline characteristics: median age 54; male 56%; primary tumor site: skin 73%, mucosal 10%, unknown 17%; BRAFV600 mutation 56%; AJCC stage IV M1c 81%; brain metastases 27%; LDH > ULN 27%. Median follow-up (FU) so far is 25 weeks (range: 14-30 weeks). Treatment related grade ≥ 3 AEs occurred in 29.3% of the patients; most prevalent grade 3 or 4 AEs were colitis (17%), increased ALT/AST (5%), maculopapular rash (5%) and nephritis (2%). In 7 patients (17%) treatment was discontinued due to toxicity. Of the 41 patients included, 35 were evaluable for response. BORR was 54.3% (95%CI: 37-71) and DCR 71.4% (95%CI: 54-85). Updated results will be presented at ASCO. Conclusions: Treatment with short-term IPI directly followed by NIV/PEM may have similar efficacy but lower toxicity as compared to concomitant therapy with IPI plus NIV. If these results persist with longer FU, this regimen should be tested versus concomitant IPI plus NIV in a prospective randomized controlled clinical trial.
Angela M.H. Brodie, PhD, FAACR: In Memoriam (1934–2017)
Authors: V. Craig Jordan
Journal: Cancer Research (2017)

![][1] 

On June 7, 2017, the cancer research community lost Professor Angela MH Brodie, PhD, FAACR, the “Mother of Aromatase Inhibitors.” The discovery of specific aromatase inhibitors (AI) is a major advance in targeted therapeutics. Three cheap orally active agents, anastrozole,
Regional Differences Between Perisynovial and Infrapatellar Adipose Tissue Depots and Their Response to Class II and III Obesity in Patients With Osteoarthritis: Comment on the Article by Harasymowicz et al
Authors: Veronica Macchi, Andrea Porzionato, Marco Rossato, Raffaele De Caro
Journal: Arthritis & Rheumatology (2017)

Harasymowicz et al (1) are to be congratulated for their recent article regarding the presence of regional differences between perisynovial and infrapatellar adipose tissue depots and their response to Class II and III Obesity in Patients with osteoarthritis (OA). The Authors report that the infrapatellar fat pad (IFP) and synovium adipose tissue depots differ significantly and are influenced by the patient's BMI. In particular, obese patients’ adipocytes from IPF are significantly larger while in the synovium, there was marked fibrosis, macrophage infiltration and higher TLR4 expression identified in comparison to lean subjects. We would like to share our anatomical experience on adipocytes of IPF (2).

This article is protected by copyright. All rights reserved.
A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice
Authors: Megan N. Roberts, Marita A. Wallace, Alexey A. Tomilov, Zeyu Zhou, George R. Marcotte, Dianna Tran, Gabriella Perez, Elena Gutierrez-Casado, Shinichiro Koike, Trina A. Knotts, Denise M. Imai, Stephen M. Griffey, Kyoungmi Kim, Kevork Hagopian, Marissa Z. McMackin, Fawaz G. Haj, Keith Baar, Gino A. Cortopassi, Jon J. Ramsey, Jose Alberto Lopez-Dominguez
Journal: Cell Metabolism (2017)
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Authors: T. B. Casale, B. E. Chipps, K. Rosén, B. Trzaskoma, T. Haselkorn, T. A. Omachi, S. Greenberg, N. A. Hanania
Journal: Allergy (2017)

Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy.Data from two phase III clinical trials of omalizumab in patients with allergic asthma were examined. Differences in rates of asthma exacerbations between omalizumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were evaluated with respect to baseline blood eosinophil counts (eosinophils <300/μL [low] vs ≥300/μL [high]) and baseline markers of asthma severity (emergency asthma treatment in prior year, asthma hospitalization in prior year, forced expiratory volume in 1 second [FEV1 ; FEV1 <65% vs ≥65% predicted], inhaled beclomethasone dipropionate dose [<600 vs ≥600 μg/day], and long-acting beta-agonist [LABA] use [yes/no]).Adults/adolescents (N = 1071) were randomized to receive either omalizumab (n = 542) or placebo (n = 529). In the 16-week ICS dose-stable phase, rates of exacerbations requiring ≥3 days of systemic corticosteroid treatment were 0.066 and 0.147 with omalizumab and placebo, respectively, representing a relative rate reduction in omalizumab-treated patients of 55% (95% CI, 32%-70%; P = .002). For patients with eosinophils ≥300/μL or with more severe asthma, this rate reduction was significantly more pronounced.In patients with allergic asthma, baseline blood eosinophil levels and/or clinical markers of asthma severity predict response to omalizumab.
ERKs activation by PARs that is independent of EGFR transactivation in colon cancer cell proliferation
Authors: Valérie Gratio, Eunice Nubret, Mai Nguyen Thi Thanh, Marc Laburthe, Dalila Darmoul
Journal: Cancer Research (2006)

76   Serine proteases elicit cellular effects by activating G protein-coupled protease-activated receptors (PARs). The PAR family includes four members: PAR1, PAR2, PAR3 and PAR4. PARs are activated by an unusual irreversible proteolytic event in which the protease binds to and cleaves the amino-terminus of the receptor generating a new amino terminus that functions as a tethered ligand. This activation initiates signal transduction resulting in stimulation of phosphoinositide breakdown and cytosolic calcium mobilization leading to the activation of MEK-ERK1/2. Our recent studies have shown the implication of proteinase-activated receptors (PARs) in colon cancer  (Darmoul et al. Br. J. Cancer 2001; Am J Pathol., 2003) .Using the HT29 colon cancer cell line, we identified a cross-talk between proteinase activated receptors and epidermal growth factor receptor  (Darmoul et al. J. Biol. Chem. 2004) . This cross talk explains the activation of ERK signal transduction pathway and the proliferative effects induced by serine proteases in colon cancer cells. In this study we show that : 1) the mechanism of EGFR transactivation is not a general mechanism since it is found only in 50% of the colon cancer cell lines analyzed. Indeed, AG1478, the EGFR tyrosine kinase inhibitor abrogated the PAR induced ERK phosphorylation in HT29, T84 and Caco2 cells. In contrast, this inhibitor has no effect on the PARs-induced ERKs phosphorylation in other colon cancer cells such as HCT116, SW480 and LoVo cells; 2) we did not find any correlation between the expression level of the EGFR receptor on the cell membrane and the involvement of the EGFR as a transducer molecule; 3) PKC is not involved in ERKs activation. Indeed, the PKC inhibitor GF10903X has no effect on ERKs activation induced by PARs in some colon cancer cells. We conclude that PARs induce ERKs activation and subsequent colon cancer cell proliferation through both EGFR-dependent and-independent pathways. Thus PARs stimulate a non described pathway to activate ERKs in some colon cancer cells.
Tachyarrhythmia Onset Captured on Telemetry Deciphers the Diagnosis
Authors: Maen D. Abou Ziki, Lynda E. Rosenfeld
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Authors: David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Søren S. Lund
Journal: Kidney International (2017)
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings
Authors: Domenico Lepore, Graham E. Quinn, Fernando Molle, Lorenzo Orazi, Antonio Baldascino, Marco H. Ji, Maria Sammartino, Fabio Sbaraglia, Daniela Ricci, Eugenio Mercuri
Journal: Ophthalmology (2017)
Long term study backs statins for patients with high LDL and no other risk factors
Authors: Jacqui Wise
Journal: BMJ (2017)

Treatment with statins reduced deaths from coronary heart disease by 28% in men with very high levels of low density lipoprotein (LDL) cholesterol but no other risk factors or signs of heart disease, a 15 year follow-up study has reported in the journal Circulation .1

The authors said that the findings provide the first direct randomised trial evidence to confirm current guidance that patients with LDL above 190 mg/dL should be considered for statin treatment regardless of other risk factors.

Kausik Ray, the study leader, from Imperial College London’s School …
Evidence-Based Practice
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hydrogen-Ion Concentration of Normal Liver and Hepatic Tumors
Authors: Herbert Kahler, William v. B. Robertson
Journal: JNCI Journal of the National Cancer Institute (1943)

Hydrogen-Ion Concentration of Normal Liver and Hepatic Tumors Herbert Kahler, Herbert Kahler senior biophysicist Search for other works by this author on: Oxford Academic PubMed Google Scholar William v. B. Robertson William v. B. Robertson research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 5, June 1943, Pages 495–501, https://doi.org/10.1093/jnci/3.5.495 Published: 01 June 1943
Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab
Authors: Carla Casulo, Juan-Manuel Sancho, Koen Van Eygen, Sven de Vos, Santiago Mercadal, Roderick J. Johnson, Kamal Bouabdallah, Houston Holmes, Jan Lemmens, Emmanuel Gyan, Michele Merli, Ranjana H Advani, Lori Steelman, Joseph Pearlberg, Andre Goy
Journal: Blood (2016)
Testosterone Replacement Therapy and Cardiovascular Risk—A Closer Look at Additional Parameters
Authors: Konstantinos Stavropoulos, Konstantinos P. Imprialos, Michael Doumas
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal